Biotech startups escaped the volatility that has defined venture capital over the past three years, maintaining a consistent funding moat even as artificial intelligence consumed investor attention and capital flows. Global biotech funding remained anchored between $36 billion and $40 billion annually, a resilience that stands in sharp contrast to the feast-or-famine dynamics seen across other sectors.
Crunchbase data indicates 2026 is tracking to sustain this plateau. While AI commanded outsized headlines and venture dollars, biotech investors continued writing checks at steady levels, suggesting the sector operates on different fundamentals than hype-driven categories. The stability reflects several structural factors. Drug development timelines remain long and capital intensive, forcing institutional investors to maintain discipline regardless of market sentiment. Regulatory frameworks provide predictability. Patent portfolios and clinical progress generate tangible milestones that anchor valuations in ways that AI companies often cannot.
The contrast with AI funding proves instructive. Since late 2022, artificial intelligence startups witnessed explosive growth followed by severe contraction and rebalancing. Mega-rounds became routine, then nearly disappeared. Valuations inflated and then corrected sharply. Market cycles hit hard and fast. Biotech simply did not participate in this volatility. The sector attracted committed capital from dedicated biotech-focused VCs, corporate venture arms, and established institutions with long time horizons. These investors understood the sector's dynamics and did not chase narrative shifts.
This stability does not signal stagnation. Within the $36 billion to $40 billion range, capital allocation evolved. Earlier stage funding faced headwinds as investors favored later-stage companies with validated technology and de-risked development programs. Series A and B funding grew more competitive. Therapeutic areas with clear market demand and lower technical risk drew disproportionate investor interest. Companies pursuing drug repositioning or incremental therapeutic advances outcompeted moonshot bets on novel modalities.
The consistency also masked regional shifts. European biotech, particularly in the UK and Switzerland, grew as a proportion of global funding. Asian biotech, driven by China and Singapore, accelerated. The United States remained dominant but saw its share stabilize rather than grow, a shift partly explained by a more crowded funding landscape and higher operating costs.
Investors signaled clear preferences. Startups pursuing cancer, immuno-oncology, and rare diseases attracted robust interest. Gene therapy startups faced skepticism following clinical setbacks and manufacturing challenges, though select programs continued to raise capital. Cell therapy remained hot but consolidated among better-capitalized teams. Companies with experienced founders and prior exits secured capital more readily. First-time founders in biotech faced genuine headwinds.
The AI boom actually benefited certain biotech subsectors. Computational biology and AI-enabled drug discovery drew interest from both traditional biotech VCs and tech-focused investors. Platforms using machine learning for target identification or lead optimization found receptive audiences. These hybrid plays attracted capital that blended biotech rigor with tech-sector enthusiasm.
Looking ahead, biotech's funding stability likely persists. The sector's structural requirements for capital, regulatory oversight, and patient outcomes create natural investor discipline absent in faster-moving categories. While AI funding eventually may reach equilibrium, biotech has already found its baseline. The sector offers institutional investors a reliable category for deploying capital across market cycles, a quality increasingly rare in venture capital.